Hertzen Moscow Oncology Research Center

Moscow 125284

0 studies enrolling now · 2 studies all time

What they study most

Clear Cell Renal Cell Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Studies at this site

• A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread — Running, not enrolling
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Running, not enrolling